Azithromycin in the Prevention of Lung Injury in Premature Newborn

Bronchopulmonary Dysplasia Clinical Trial

Official title:

Randomized Clinical Trial: Use of Azithromycin to Prevent Lung Damage in Preterm Newborns Under Mechanical Ventilation

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03485703
• Other study ID #: 110639
• Status: Completed
• Phase: Phase 4
• First received: March 25, 2018
• Last updated: March 25, 2018
• Start date: August 28, 2012
• Est. completion date: April 13, 2016

Study information

• Verified date: March 2018
• Source: Hospital de Clinicas de Porto Alegre
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The introduction of invasive mechanical ventilation in the treatment of preterm infants works as an adjuvant in the treatment of acute respiratory failure, which has resulted in significantly significant survival rates. In recent years there has been an increase in the number of evidence that mechanical factors can cause lung injury through inflammatory cells and soluble mediators.

The alveolar and airway epithelium is an important source of cytokine release. Cytokines are very low molecular weight proteins or glycoproteins with hormone-like actions. They contribute to the pathogenesis of various diseases through the ability to induce other inflammatory mediators Mechanical ventilation strategies can increase pulmonary and systemic cytokines and lead to dysfunction of multiple organs and systems.

Azithromycin has a potent anti-inflammatory and immunomodulatory effect It suppresses the production of proinflammatory cytokines (IL-6, IL-1, and TNF-α), has effective antimicrobial properties against Ureaplasma and, best of all, few side effects The hypothesis of this study is that azithromycin would reduce pulmonary inflammation induced by mechanical ventilation in premature infants, conferring a protective character.Randomized clinical trial: use of azithromycin in preventing pulmonary damage newborn preterm undergoing mechanical ventilation

Description:

The nature of lung injury induced by mechanical ventilation is clearly established, including the release of immunoinflammatory mediators. However, safe drug therapy that decreases its severity is not available. Azithromycin is a macrolide antibiotic with potent anti-inflammatory effects, but has been poorly studied in preterm infants except for very few studies in extreme preterms for the prevention of bronchopulmonary dysplasia.

The aim of this study was to evaluate the effect of azithromycin on the prevention of cytokine-mediated MV-induced injury in cytokine plasma levels (IL-1β, IL-2, IL-6, IL-8, IL-10 and TNF- α) in preterm newborns, submitted to mechanical ventilation in the first 72 hours of life.

It is a double-blind placebo controlled clinical trial. When the use of azithromycin was considered, after signing the informed consent, a randomization was performed by the intravenous mixtures center of Hospital de clinicas de porto alegre where a group of newborns will receive azithromycin EV at the dose of 10mg / kg / day and another group will receive placebo (SF 0.9%) in the same volume, a blood aliquot of 300μL will be collected in all ETDA for cytokine analysis and PCR for Ureaplasma. After 5 days of starting azithromycin or placebo, a new sample will be collected for cytokines along with blood collection from the patient's routine. There will be no blood collection exclusively for the study.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 80
• Est. completion date: April 13, 2016
• Est. primary completion date: April 13, 2016
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: N/A to 72 Hours

Eligibility

Inclusion Criteria:

• preterm infants of less than 37 weeks of gestational age who have undergone mechanical ventilation within the first 72 hours of life

Exclusion Criteria:

• Major congenital malformations or chromosomal syndromes Mothers carrying the HIV virus.

Related Conditions & MeSH terms

• Bronchopulmonary Dysplasia

Intervention

Drug:
• Azithromycin
the newborn group will receive intravenous azithromycin 10 mg / kg / day once daily for 5 days
• Placebo
the group of newborns will receive 0.9% saline once daily for 5 days

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Hospital de Clinicas de Porto Alegre

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	bronchopulmonary dysplasia	neonate that needs to use oxygen in concentrations above 21% for a period greater than or equal to 28 days	28 days
Secondary	TNF	decreasing in plasma levels after treatment with azitromicina	5 days
Secondary	IL-10	increasing in plasma levels after treatment with azitromicina	5 days
Secondary	IL-6	increasing in plasma levels after treatment with azitromicina	5 days
Secondary	IL-8	increasing in plasma levels after treatment with azitromicina	5 days
Secondary	IL1b	increasing in plasma levels after treatment with azitromicina	5 days
Secondary	IL2	increasing in plasma levels after treatment with azitromicina	5days